anlak storytelling
All kinds
Document kinds
Loading document kinds...

Primary corpus lens for browsing and insights. Selection lives in the URL.

All formats
Orientation
Loading formats...

Landscape, portrait, square, or unknown document geometry.

Unlock
slides · global inventory

Callout

Component collection for the active corpus filters, with each row opening the slide detail view.

Search Insights JSON Unlock
Matching slides 96,741
Current window 75,601-75,630
Pages 3,225
Rows per page 30
Component: Calloutclear collectionreset all
18 30 60

Component

75,601-75,630 of 96,741

filter-aware
311
The slide uses a Q&A format to document expert testimony regarding trial integrity.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
312
The slide uses a direct quote from an endocrinologist to cast doubt on the company's clinical data integrity.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
313
The slide uses a Q&A format to highlight the expert's skepticism about the company's reporting practices.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
315
Includes verbatim Q&A transcripts highlighting the investigator's passive approach to patient recruitment.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
316
The slide uses Q&A transcripts to undermine the perceived market success of the drug.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
317
The slide uses direct quotes from a trial investigator to undermine the drug's clinical value and commercial prospects.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
318
The slide uses a 'quote-as-evidence' structure to undermine the clinical efficacy of the drug.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
319
The slide uses a Q&A transcript format to expose flaws in clinical trial integrity.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
321
The slide uses a Q&A transcript format to expose flaws in the clinical trial design regarding pill size.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
322
The slide uses a Q&A transcript format to undermine the company's product value proposition.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
323
The slide uses a combination of summary text and direct interview transcripts to highlight expert skepticism.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
324
The slide uses a Q&A format to highlight the failure of the trial's blinding protocol.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
325
The slide uses direct quotes from a pediatric endocrinologist to build a case against the drug's safety profile.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
326
The slide uses Q&A transcripts to expose the risks of the drug and the burden of monitoring.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
327
The slide uses a bolded summary paragraph at the top, followed by a detailed Q&A transcript with yellow highlighting on key quotes.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
328
The slide uses a Q&A transcript format to support the thesis that the competitor product is unnecessary or inferior.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
329
The slide uses a Q&A format to document expert testimony.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
330
Includes direct Q&A transcripts from a trial investigator/endocrinologist.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
331
The slide uses direct quotes from an endocrinologist/KOL to undermine the clinical trial results.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
332
The slide uses a direct quote from an endocrinologist to undermine the primary endpoint of a clinical trial.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
333
The slide uses direct quotes from a trial investigator to undermine the company's value proposition.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
334
The slide uses direct quotes from a trial investigator to undermine the value proposition of the drug Vykat.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
335
The slide uses direct quotes from an interview to highlight the discrepancy between public promotion and private clinical reality.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
337
Uses direct quotes from an investigator to undermine the credibility of clinical trial data.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
338
The slide uses a Q&A transcript format to highlight potential misclassification of adverse events in a clinical trial.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
340
The slide presents a transcript of an expert consultation call to undermine the market potential of Vykat.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
342
The slide uses a Q&A format to highlight the expert's negative sentiment toward the drug's efficacy and the company's investor materials.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
343
The slide presents a direct challenge to the commercial viability of 'Vykat' by highlighting a physician's preference for a cheaper, off-label alternative.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
344
The slide uses a Q&A format to validate the expert's critique of the product's form factor.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
346
The slide uses highlighted text to emphasize critical quotes from medical experts.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit